Patients with recent MI were at higher risk of CV events and tended to have greater ARRs with evolocumab compared to those with remote MIs, as shown in this secondary analysis of the FOURIER trial.

Prof. Jukema explains the main principles for LDL-c-lowering therapy as described in the 2019 ESC/EAS guidelines and discusses results from several trials that investigated the effect of Lp(a) on CV outcomes.

The PCSK9 inhibitor evolocumab significantly reduced risk of MI across multiple MI subtypes and sizes, as shown by an analysis of the FOURIER trial.

Evolocumab had no significant impact on patient-reported cognition, compared to placebo. No association was found between achieved LDL-C at 4 weeks and subsequent cognitive function.

Elevated Lp(a) contributes to pro-inflammatory gene expression of monocytes in both healthy subjects and CVD patients. Potent Lp(a)-lowering reduced the pro-inflammatory state of circulating monocytes.

The largest cardiology congress ESC was just announced to turn fully digital. PACE-CME is committed to help sharing the news and deliver our cardiovascular education

Inclisiran, an siRNA against PCSK9, did not result in adverse effects on measures of inflammation, immune activation and platelets. No clinical immunogenicity AEs were observed.

ACC 2020 This post-hoc analysis showed an association between increased Lp(a) and increased risk of aortic stenosis events. Evolocumab reduced risk of aorta stenosis after 1-year treatment.

ACC 2020 This trial showed that evolocumab treatment of dyslipidemic people living with HIV reduced LDL-c and other atherogenic lipids and lipoproteins and was well tolerated and safe.

ACC 2020 This analysis showed that a genetic risk score predicts VTE risk in patients with cardiometabolic disease and that evolocumab reduces the risk for VTE in patients in the top 1/3 of genetic risk.

ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.